Paper Details

  1. Home
  2. Paper Details

Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD.

Author: AndersonDavid, BaughBryan, BejouNika, CampbellJennifer, DunnKeith, LuoDonghan, SeyedkazemiSareh

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This post-hoc analysis evaluated gastrointestinal adverse events of interest in patients receiving darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF). The findings suggest that the incidence and prevalence of these events were low and tended to present early.
Paper Details　
Original Abstract of the Article :
Gastrointestinal intolerance has been associated with ritonavir-boosted protease inhibitors. This post hoc analysis evaluated gastrointestinal adverse events of interest (AEOIs; diarrhea, nausea, abdominal discomfort, flatulence [MedDRAv21]) through Wk96 among patients enrolled in the phase 3 AMBER ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044782/

データ提供：米国国立医学図書館（NLM）

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide - A New HIV Treatment Option

This research explores the gastrointestinal side effects of a new HIV treatment regimen, darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF). The study finds that the incidence of gastrointestinal adverse events was low and tended to occur early in treatment, suggesting that this regimen may be well-tolerated for many patients.

D/C/F/TAF - A Promising HIV Treatment

The research suggests that D/C/F/TAF may be a viable and well-tolerated treatment option for HIV infection. The study's findings provide encouraging evidence for the safety and efficacy of this new regimen.

HIV Treatment - A Journey of Progress

The development of new HIV treatments is a testament to the ongoing progress in combating this global health challenge. This research provides valuable insights into the safety and tolerability of D/C/F/TAF, offering hope for individuals living with HIV.

Dr.Camel's Conclusion

Just like a camel adapts to the diverse landscape of the desert, HIV treatment options continue to evolve. This research explores the safety and tolerability of D/C/F/TAF, providing a glimmer of hope for individuals navigating the challenges of living with HIV.

Date :
  1. Date Completed 2022-04-27
  2. Date Revised 2022-07-16
Further Info :

Pubmed ID

35466761

DOI: Digital Object Identifier

PMC9044782

Related Literature

Article Analysis
・Effects of darunavir and cobicistat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.